News

An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…

Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…

A new artificial intelligence (AI) model based on clinical data along with laboratory results and ultrasound images aids the early diagnosis of biliary atresia,…

The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…

Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…

The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…

Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…

A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…

The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…

The Scottish Medicines Consortium (SMC) has agreed that Ipsen’s Iqirvo (elafibranor) be covered by the country’s public National Health Service (NHS), making the therapy…